3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
7
Melanoma
7
Lung Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Rectal Neoplasms
3
Head and Neck Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Neoplasm, Residual
2
Hyperthermia
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Pneumonitis
1
Interventions
Cisplatin
24
Carboplatin
19
Paclitaxel
18
pembrolizumab
12
Gemcitabine
12
Radiotherapy
9
Fluorouracil
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
cemiplimab
6
Platinum
6
Nivolumab
6
Docetaxel
6
Cetuximab
6
1,2-diaminocyclohexaneplatinum II citrate
6
epothilone B
5
anlotinib
5
Sunitinib
5
Pemetrexed
5
Oxaliplatin
5
Everolimus
5
Drug Therapy
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
durvalumab
4
Radiotherapy, Intensity-Modulated
4
Radiation
4
Erlotinib Hydrochloride
4
Celecoxib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled